| Name | Title | Contact Details |
|---|
Central Brace and Limb Co. is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Executive Health Exams International is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Action Sport Physio sports medicine clinics are renowned for the excellent results in the treatment of their patients rehabilitation needs. With a network of clinics across the province, our 400 multidisciplinary health professionals are available and accessible to provide the very best of quality care.
WellBe Senior Medical specializes in caring for patients with complex, chronic conditions, whose health is changing with age. As geriatric specialists, we have decades of experience serving these patients. We are committed to providing personal, Complete Care™ at home or anywhere our patients are, and our care team works together with patients, caregivers and physicians to nurture all aspects of health. The care we provide is sponsored by health plans and free to our patients.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.